Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients

DM Claassens; GJ Vos; C Boersma; T Bergmeijer; R Hermanides; A van 't Hof; P Van der Harst; E Barbato; C Morisco; RMTJ Gin; FW Asselbergs; A Mosterd; J-P Herrman; W Dewilde; MJ Postma; VH Deneer; JM ten Berg

doi:https://doi.org/10.1161/circ.142.suppl_3.16390

Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients

DM Claassens, GJ Vos, C Boersma, T Bergmeijer, R Hermanides, A van 't Hof, P Van der Harst, E Barbato, C Morisco, RMTJ Gin, FW Asselbergs, A Mosterd, J-P Herrman, W Dewilde, MJ Postma, VH Deneer, JM ten Berg

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Article number	A16390
Journal	Circulation
Volume	142
Issue number	Suppl. 3
DOIs	https://doi.org/10.1161/circ.142.suppl_3.16390
Publication status	Published - 1 Dec 2020
Externally published	Yes

Access to Document

https://doi.org/10.1161/circ.142.suppl_3.16390

Cite this

Claassens, DM., Vos, GJ., Boersma, C., Bergmeijer, T., Hermanides, R., van 't Hof, A., Van der Harst, P., Barbato, E., Morisco, C., Gin, RMTJ., Asselbergs, FW., Mosterd, A., Herrman, J.-P., Dewilde, W., Postma, MJ., Deneer, VH., & ten Berg, JM. (2020). Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients. Circulation, 142(Suppl. 3), Article A16390. https://doi.org/10.1161/circ.142.suppl_3.16390

@article{e9adb7cbe1574fbc8ce2dc21cba60a01,

title = "Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients",

author = "DM Claassens and GJ Vos and C Boersma and T Bergmeijer and R Hermanides and {van 't Hof}, A and {Van der Harst}, P and E Barbato and C Morisco and RMTJ Gin and FW Asselbergs and A Mosterd and J-P Herrman and W Dewilde and MJ Postma and VH Deneer and {ten Berg}, JM",

year = "2020",

month = dec,

day = "1",

doi = "https://doi.org/10.1161/circ.142.suppl_3.16390",

language = "English",

volume = "142",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "Suppl. 3",

}

Claassens, DM, Vos, GJ, Boersma, C, Bergmeijer, T, Hermanides, R, van 't Hof, A, Van der Harst, P, Barbato, E, Morisco, C, Gin, RMTJ, Asselbergs, FW, Mosterd, A, Herrman, J-P, Dewilde, W, Postma, MJ, Deneer, VH & ten Berg, JM 2020, 'Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients', Circulation, vol. 142, no. Suppl. 3, A16390. https://doi.org/10.1161/circ.142.suppl_3.16390

TY - JOUR

T1 - Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients

AU - Claassens, DM

AU - Vos, GJ

AU - Boersma, C

AU - Bergmeijer, T

AU - Hermanides, R

AU - van 't Hof, A

AU - Van der Harst, P

AU - Barbato, E

AU - Morisco, C

AU - Gin, RMTJ

AU - Asselbergs, FW

AU - Mosterd, A

AU - Herrman, J-P

AU - Dewilde, W

AU - Postma, MJ

AU - Deneer, VH

AU - ten Berg, JM

PY - 2020/12/1

Y1 - 2020/12/1

U2 - https://doi.org/10.1161/circ.142.suppl_3.16390

DO - https://doi.org/10.1161/circ.142.suppl_3.16390

M3 - Meeting Abstract

SN - 0009-7322

VL - 142

JO - Circulation

JF - Circulation

IS - Suppl. 3

M1 - A16390

ER -